Your browser doesn't support javascript.
loading
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter, Tamás; Klippel, Zandra; Cesas, Alvydas; Croitoru, Adina; Decaestecker, Jochen; Gibbs, Peter; Hotko, Yevhen; Jassem, Jacek; Kurteva, Galina; Novotny, Jan; O'Reilly, Seamus; Salek, Tomas; Reiner, Maureen; Morrow, Phuong Khanh; Choi, Mi Rim; Whittaker, Sadie; Blanke, Charles.
Affiliation
  • Pinter T; Department of Oncoradiology, Petz Aladár Teaching Hospital, Györ, Hungary. Electronic address: pinterbely@gmail.com.
  • Klippel Z; Clinical Development, Amgen Inc, Thousand Oaks, CA.
  • Cesas A; Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania.
  • Croitoru A; Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania.
  • Decaestecker J; Department of Oncology, AZ Delta Hospital, Roeselare, Belgium.
  • Gibbs P; Department of Oncology, The Western Hospital, Footscray, Victoria, Australia.
  • Hotko Y; Uzhgorod Regional Oncology Dispensary, Uzhgorod National University, Uzhgorod, Ukraine.
  • Jassem J; Department of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland.
  • Kurteva G; Clinic of Medical Oncology, Specialized Hospital for Active Treatment in Oncology Sofia, Sofia, Bulgaria.
  • Novotny J; Department of Oncology, Institute of Oncology and Rehabilitation, Nová Ves pod Plesí, Czech Republic.
  • O'Reilly S; Department of Medical Oncology, Ireland Cooperative Oncology Research Group, Dublin, Ireland.
  • Salek T; Department of Clinical Oncology, National Cancer Institute, Bratislava, Slovakia.
  • Reiner M; Global Biostatistical Sciences, Amgen Inc, Thousand Oaks, CA.
  • Morrow PK; Clinical Development, Amgen Inc, Thousand Oaks, CA.
  • Choi MR; Clinical Development, Amgen Inc, Thousand Oaks, CA.
  • Whittaker S; Clinical Development, Amgen Inc, Thousand Oaks, CA.
  • Blanke C; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR.
Clin Colorectal Cancer ; 16(2): 103-114.e3, 2017 06.
Article in En | MEDLINE | ID: mdl-28038865
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polyethylene Glycols / Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Febrile Neutropenia / Filgrastim Type of study: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 Language: En Journal: Clin Colorectal Cancer Journal subject: GASTROENTEROLOGIA / NEOPLASIAS Year: 2017 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polyethylene Glycols / Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Febrile Neutropenia / Filgrastim Type of study: Clinical_trials / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 Language: En Journal: Clin Colorectal Cancer Journal subject: GASTROENTEROLOGIA / NEOPLASIAS Year: 2017 Document type: Article Country of publication: United States